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Abstract
Introduction: Breast cancer currently accounts for more than one-quarter of all female cancers and, despite the
great progress in treatment observed in the past few years, the need for identification of new gene targets that
can be used for diagnosis, prognosis and therapy is evident. A previous study identified the transcription factor
NR4A1 as a gene upregulated in primary breast cancer compared with normal tissue by microarray analysis and
sequencing technologies. The purpose of the study was to identify the role of NR4A1 in normal mammary
epithelial and breast cancer cell biology.
Methods: NR4A1 expression in breast tumours was assessed by semiquantitative and real-time PCR using RNA
from normal and tumour samples or breast cancer cell lines. Immunohistochemistry on tissue microarrays was
performed to check NR4A1 protein expression in breast tumours. MCF-10A and 226L normal mammary epithelial
cells as well as the tumour lines PMC42, ZR-75-1 and MDA-MB-231 were transduced with full-length NR4A1, and
the ability of NR4A1-overexpressing cells to migrate was tested using scratch wound or transwell migration assays.
Proliferation was measured using the MTT and BrdU assays, while apoptosis was determined by the Annexin V
assay. The ability of the cells to adhere to extracellular matrix was tested by adhesion assays and integrin cell
surface expression was measured by flow cytometry. Activation of the FAK as well as ERK1/2 and PI3K pathways
was checked by western blotting.
Results: Breast tissue microarray analysis showed NR4A1 expression in primary tumours, which was reduced in
higher grade and metastatic tumours. Ectopic expression of NR4A1 in MCF-10A, 226L, PMC42 and ZR-75-1 cells led
to reduced ability of the cells to migrate, while no differences were observed in their proliferation and apoptotic
index. NR4A1 expression altered the ability of the MCF-10A cells to adhere to the extracellular matrix and affected
cell surface expression of integrins.
Conclusions: NR4A1 acts as an antimigratory factor in two normal mammary epithelial and two breast cancer cell
lines tested. It is therefore possible that NR4A1 acts as an antimigratory factor in breast tumours, and further
studies should be conducted to understand the mechanisms involved.
Introduction
Transcription factors are a family of proteins that regu-
late gene expression at different stages of embryonic
development and are key to the establishment and
maintenance of specific cell phenotypes. Consequently,
their expression may have an important role in defining
the neoplastic phenotype of an individual tumour. Dis-
secting transcriptional networks and targeting aberrantly
expressed transcription factors has already become an
important paradigm for cancer therapy, the oestrogen
receptor being an important example.
Breast cancer is a clinically and structurally heteroge-
neous disease. The tumour itself consists of many differ-
ent cell types, including normal and reactive stromal
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terminal duct-lobular unit is considered the origin of
most cancers and consists of two morphologically recog-
nisable cell types: epithelial cells on the inner luminal
surface, surrounded by an outer layer of contractile
myoepithelial (basal) cells. While typical breast cancers
have been regarded traditionally as exhibiting character-
istics akin to luminal epithelial cells, recent data have
shown that some also exhibit, in part or whole, myo-
epithelial/basal features [3-5].
Gene expression profiling of RNA from solid hetero-
geneous breast tumours has enabled their classification
into at least five different types [6,7] and gene signatures
have been defined that are indicative of poor prognosis
[8-10]. However, the precise nature of the RNA changes
in the various types of cancer cells-even with prior laser
microdissection capabilities - still remains elusive.
Our approach to ascertain the alterations present only
in cancer cells has involved the use of immunomagnetic
methods to separate malignant cells from other contam-
inating nonmalignant and stromal cell types within can-
cers, and also to separate the normal luminal and
myoepithelial cells from fibroblasts, immune and
endothelial cells within reduction mammoplasty material
[11-13]. RNA extracted from purified luminal, myoe-
pithelial and malignant cells from multiple donors was
profiled using a multi-platform expression analysis,
involving a combination of massively parallel signature
sequencing and four different array-based genome-wide
methods [12]. This has yielded what is probably the
most comprehensive catalogue of genes whose levels are
altered in breast cancer cells and whose expression can
be annotated with respect to whether they represent
luminal or myoepithelial type genes, free from the com-
plexities due to the presence of normal and activated
stromal cells present in solid tumour samples. This
resulting differential tumour epithelial transcriptome
(DTET) comprised 8,051 genes that were either upregu-
lated or downregulated in the malignant epithelial cells.
Ontological analysis has enabled these genes to be clas-
sified into different functional categories - the largest
functional group of upregulated transcripts corre-
sponded to genes associated with transcription and reg-
ulation of transcription, with potential to significantly
influence the biology of a cancer cell by causing large-
scale changes in gene expression [12].
In the present article we explore the role in mammary
cell biology of one transcription factor, namely NR4A1,
by its ectopic expression in normal mammary epithelial
cells and breast cancer cell lines. NR4A1 expression
reduces migration in both normal and tumour lines, as
well as altering adhesion to the extracellular matrix
(ECM) and integrin cell surface expression in MCF-10A
cells, suggesting that NR4A1 may have an inhibitory
role in relation to invasion/metastasis development.
Materials and methods
Materials
Antibodies against NR4A1 (clone P15 and M210) were
obtained from Cell Signalling (Danvers, MA, USA) and
Santa Cruz (Heidelberg, Germany). Antibodies against a5
integrin (P1D6) and a6 integrin (GOH3) were from Santa
Cruz. Antibodies against a1 integrin (FB12), a2 integrin
(P1E6), b1 integrin (P4C10), b4 integrin (3E1), avb3
integrin (LM609) and avb6 integrin (10D5) were
obtained from Millipore (Watford, UK). The antibody
against EMA (ICR2) was from Seralab (Leicestershire,
UK), while the antibody against b4 integrin (A9) was
from Santa Cruz. The Alexa-488 conjugated secondary
antibodies were obtained from Invitrogen (Paisley, UK).
Rabbit monoclonal or polyclonal antibodies against
pERK1/2, total ERK1/2, pAKT, total AKT, pFAK (Y397)
and total FAK were obtained from Cell Signalling. The
anti-b-tubulin antibody, fibronectin (human plasma),
vitronectin (bovine plasma), insulin, hydrocortisone, epi-
dermal growth factor (EGF) and b-oestradiol were from
Sigma-Aldrich (Dorset, UK). Collagen I (rat tail) was
from BD Biosciences (Oxford, UK) and laminin I was
from R & D (Abingdon, UK). DMEM/F12, DMEM, Lei-
bovitz’s medium and soybean trypsin inhibitor were from
Invitrogen. Cholera toxin was from Biomol (Exeter, UK).
Preparation of RNA from normal breast and tumours
Ten reduction mammoplasties were used to sort luminal
epithelial cells by magnetic activated cell sorting (Milte-
nyi Biotec, Bisley, UK) as described previously [12].
Luminal epithelial cells were positively sorted using an
antibody against the luminal marker EMA (clone ICR2)
and were negatively sorted using an antibody against b4
integrin (clone A9).
The 226L normal mammary epithelial cell line was
derived by immortalising sorted luminal cells with retro-
viruses that transduced SV40 large T antigen and the
catalytic subunit of human telomerase [14].
Fifty-six primary grade 2 and grade 3 infiltrating duc-
tal carcinomas were isolated as previously described
[12]. RNA was extracted from 36 of the above tumour
samples. RNAs were pooled for the first round of RT-
PCR validation, while individual samples were used for
the second round of RT-PCR validation.
Immunomagnetic cell sorting was performed for 20
out of the 56 solid tumours to remove desmoplastic
fibroblasts. The tumour samples were negatively sorted
using an antibody against fibroblast activation protein
(clone F19) as previously described [12], and RNA was
extracted resulting in the F19-negative RNA samples.
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RT-PCR validation, and individual samples were used
for the second round.
A different set of F19-negative RNA samples was pre-
pared and used for the real-time PCR experiments.
Informed consent was obtained from the patients.
Samples were obtained from the Royal Marsden Hospi-
tal (London, UK) with approval from the appropriate
Ethical Committee.
Breast tissue microarray analysis
Formalin-fixed paraffin-embedded tumour blocks were
retrieved from the archives of the Pathology of Queens-
land and the Wesley Hospital in Australia, from the
Medical Faculty of Charles University in Plzen, Czech
Republic, and from the Instituto Nacional do Cancer
and Laboratorio Salomao & Zoppi in Brazil. The sam-
ples were anonymous and could not be tracked back to
the patients. The study was approved by the local
research ethics committees under project number
UQ2005000785 and RBHW 2005/22.
O n et i s s u em i c r o a r r a yp u r e l yo fl o b u l a rc a r c i n o m a s
and another two microarrays containing primary infil-
trating ductal carcinomas and corresponding brain
metastasis were built. None of these tumours relate to
t h eo n e su s e df o rR T - P C Ra n dr e a l - t i m eP C R .T i s s u e
microarrays were built using the tissue arrayer model
MTAI (Beecher Instruments, Inc., Sun Prairie, WI,
USA).
For immunohistochemistry, sections were cut at 4 μm
and mounted on silane-coated slides. Immunohisto-
chemistry was performed using the Envision dual-link
system according to the manufacturer’s( D A K O ,
Glostrup, Denmark) instructions. The polyclonal anti-
body to NR4A1 (clone M210) was used at a concentra-
tion of 1:100 and an incubation time of 60 minutes was
employed, with antigen retrieval being achieved through
the use of ethylenediamine tetraacetic acid (EDTA), pH
8.0, for 2 minutes at 105°C.
Positive (normal epithelial breast cells) and negative
(exclusion of the primary antibody from the reaction)
controls were included and the results were assessed by
two pathologists under a double-headed microscope.
Tumours were considered positive when > 10% of the
tumour cells exhibited a positively stained cytoplasm.
Nuclear staining was not observed.
Cell culture
MCF-10A cells were obtained from ATCC-LGC Stan-
dards (Teddington, UK) and were cultured in DMEM/
F12 medium supplemented with 5% horse serum, EGF
(20 ng/ml), insulin (10 μg/ml), hydrocortisone (0.5 μg/
ml) and cholera toxin (100 ng/ml). 226L cells were cul-
tured in DMEM/F12 medium supplemented with 10%
FCS, EGF (20 ng/ml), insulin (5 μg/ml), hydrocortisone
(1 μg/ml) and cholera toxin (20 ng/ml). PMC42 cells
[15,16] were cultured in the same medium as 226L cells
in the absence of cholera toxin. ZR-75-1 cells were cul-
tured in DMEM in the presence of 10% FCS and 10
-8 M
b-oestradiol. MDA-MB-231 cells, a kind gift from Dr
Tencho Tenev (The Institute of Cancer Research, Lon-
don, UK) were cultured in DMEM with 10% FCS and 2
mM glutamine. Phoenix amphotropic cells and
HEK293T cells (ATCC-LGC standards) were cultured
in DMEM supplemented with 10% FCS and 2 mM
glutamine.
Plasmid constructs, retroviral and lentiviral infections
The full-length human NR4A1 ORF (Geneservice, Cam-
bridge, UK) was cloned into the XhoI/NotIs i t e so ft h e
retroviral pLPCX vector (Clontech, Saint-Germain-en-
Laye, France). For retroviral production, Phoenix
amphotropic cells were transfected with pLPCX vector
control or pLPCX-NR4A1, using FuGENE 6 (Roche,
Mannheim, Germany). The full-length NR4A1 ORF was
also cloned into the BamHI/NotI sites of the pLEX len-
tiviral vector (Thermo Fisher Scientific, Huntsville, AL,
USA). For lentiviral production, HEK293T cells were
transfected with the pLEX or pLEX-NR4A1 following
the protocol given by the UCL RNAi consortium (Uni-
versity College London, UK). MCF-10A cells were
infected with the retroviral constructs, while all other
lines were infected with the lentiviral ones.
For viral infections, viral supernatant was applied to
t h ec e l l si nt h ep r e s e n c eo f8μg/ml polybrene (Sigma).
To obtain stable expressing cell lines, infected cells were
put under puromycin selection (1 μg/ml) 48 hours after
infection.
RNA extraction and RT-PCR
RNA was extracted using TRIzol reagent (Invitrogen)
according to the manufacturer’si n s t r u c t i o n s .R Tw a s
performed using SuperScript II (Invitrogen), and PCR
was performed using GoTaq® DNA polymerase (Pro-
mega, Southampton, UK).
Real-time PCR
Normal tissue RNA preparations were purchased from
Clontech Laboratories, Inc. (Palo Alto, CA, USA) and
Ambion, Inc. (Austin, TX, USA). RT was performed
using the Omniscript RT kit (Qiagen, Valencia, CA,
USA) according to the manufacturer’s instructions.
cDNA samples were run in duplicate for NR4A1 and for
the reference gene within the same experiment using the
Applied Biosystems apparatus 7500 Fast Real-Time PCR
system and Taqman platform (Applied Biosystems, Foster
City, CA, USA). HPRT1 was amplified as an internal refer-
ence gene. The PCR primers and probes were purchased
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independent experiments. The values obtained for each
sample from the two experiments were averaged and
everything was compared with the normal breast.
Western blot
Total protein was extracted using RIPA buffer (Sigma).
Then 35 μg protein was electrophoresed on 10% Tris-
glycine gels (Invitrogen) and transferred to nitrocellulose
(GE Healthcare, Little Chalfont, UK). After blocking
with 5% nonfat dry milk in Tris-buffered saline-Tween
for 1 hour, the membranes were incubated with primary
antibodies overnight at 4°C in 5% BSA Tris-buffered sal-
ine-Tween solution, washed and incubated with the
appropriate horseradish peroxidase-conjugated second-
ary antibodies (GE Healthcare) for 1 hour at room tem-
perature and visualised using ECL (GE Healthcare).
Blots were washed, blocked and re-blotted with an anti-
b-tubulin antibody, used as an internal loading control.
For quantification of band intensity, the gel analysis
function of ImageJ (National Institute of Health, USA)
was used and the band intensity was standardised to b-
tubulin. To determine statistical significance at each
time point, the values obtained from different experi-
ments for each cell line were compared using the paired
Student’s t test function of Microsoft Excel.
Flow cytometry analysis of integrin expression
Cells were detached with trypsin/EDTA, washed and
resuspended in flow cytometry buffer (0.5% BSA, 2 mM
EDTA). Then 1 × 10
6 cells were stained with the appro-
priate primary antibody for 20 minutes at 4°C, and were
washed and stained with secondary antibody solution
for the same period of time. Dead cells were excluded
with Topro-3 (100 nM; Invitrogen). Background fluores-
cence was measured using cells stained with secondary
antibody only. For staining with the avb6 antibody,
serum-free DMEM/F12 medium supplemented with
0.1% BSA was used throughout the procedure.
Data were collected using an LSRII flow cytometer
(BD Biosciences) and results were analysed using FloJo
software (Tree Star Inc., Ashland, Oregon, USA). The
gate for positive cells was set at 1% of the secondary-
only control cells with highest fluorescence. To compare
fluorescence intensities, the median of the fluorescence
intensity of secondary-only control cells was subtracted
from the median fluorescence intensity of the samples.
Scratch wound migration assays
MCF10A-NR4A1 cells or control cells were grown to
confluency in 35 mm wells. Wounds were scratched
using a 200 μl pipette tip and cells were washed three
times with PBS. Assay medium was then added (DMEM/
F12, 2% horse serum, 20 ng/ml EGF, insulin (10 μg/ml),
hydrocortisone (0.5 μg/ml) and cholera toxin (100 ng/
ml)). Triplicate wells were used per condition and three
fields per well were photographed at each time point
over a period of 24 hours. Scratch wound assays were
performed for cells from three independent infections.
For experiments where the MEK1/2 inhibitor U0126 was
used, confluent monolayers were treated with the inhibi-
tor 1 hour before wound initiation. Wounds were then
scratched and cells were allowed to migrate in the assay
medium supplemented with 10 μM inhibitor.
Wounds were visualised using a Nikon Eclipse TS100
microscope (Nikon, Kingston Upon Thames, UK),
images were captured using a Coolpix 4500 camera
(Nikon) and analysed by ImageJ software to calculate
the distance covered by the migrating cells. For time-
lapse microscopy, six-well plates with cells treated as
above apart from the use of Leibovitz’s medium instead
of DMEM/F12 were fixed on the stage of a Carl Zeiss
Axiovert 200 M microscope (Carl Zeiss Ltd, Hertford-
shire, UK), and cells were maintained at 37°C in the
absence of carbon dioxide. Images were captured using
a Hamamatsu Orca C4742-80 12AG camera (Hama-
matsu Photonics UK Ltd, Hertfordshire, UK), while
image acquisition was controlled by Improvision Volo-
city versions 4.4 and 5.2 (PerkinElmer, Cambridge, UK),
also used to create the QuickTime movies.
Transwell migration and invasion assays
MCF-10A cells (5 × 10
4 cells) were plated in the top
chambers of 8 μm pore transwells (BD Biosciences) in the
full culture medium minus EGF and were allowed to
migrate towards medium supplemented with 20 ng/ml
EGF over a period of 24 hours. At the end of the assay,
cells at the top chamber were removed and the cells at the
bottom of the filter were fixed with 100% ethanol for 10
minutes and stained with 0.1% crystal violet solution for
30 minutes. The dye was eluted using 33% acetic acid, and
crystal violet absorbance was measured at 590 nm. Quad-
ruplicate wells were used per condition in each experi-
ment. Transwell migration assays were performed six
times in two independent infections. For all other lines,
5×1 0
4 to 1 × 10
5 cells were plated on the top of trans-
wells in serum-free medium and were allowed to migrate
either for 8 hours (226L and MDA-MB-231 cells) or 17
hours (PMC42 and ZR-75-1 cells) towards full medium.
Experiments were repeated three times for each line.
F o rt h ei n v a s i o na s s a y st h es a m ep r o t o c o la sa b o v e
was used with matrigel-coated transwells (BD
Biosciences).
Adhesion assays
Wells of a 96-well plate were coated with 2 μg/ml fibro-
nectin, 4 μg/ml collagen type I, 8 μg/ml vitronectin, 8 μg/
ml laminin I or 1% heat-inactivated BSA for 1 hour at
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for 2 hours at room temperature. Cells were detached
using trypsin EDTA, which was inactivated with DMEM/
F12 medium supplemented with soybean trypsin inhibitor
(250 μg/ml) and 0.1 mg/ml BSA. Cells were resuspended
in serum-free DMEM/F12 medium supplemented with 0.1
mg/ml BSA. Then 2 × 10
4 cells were plated in the fibro-
nectin and collagen type I-coated wells, 4 × 10
4 cells were
plated in the vitronectin-coated wells, and 6 × 10
4 cells
were plated in the laminin I-coated wells and were incu-
bated for 40 minutes in a 37°C incubator with a 5% carbon
dioxide atmosphere. Unattached cells were removed with
two washes of PBS and the adherent cells were fixed,
stained with crystal violet and the absorbance was analysed
as for the transwell migration assay. Six wells were used
per condition in each experiment. Three or more experi-
ments were performed on each matrix. Cells from two
independent infections were used for the fibronectin
experiments.
MTT cell proliferation assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) cell proliferation assay (Invitrogen) was
performed according to the manufacturer’si n s t r u c t i o n s .
Briefly, 2 × 10
3 to 6 × 10
3 cells were plated per well of a
96-well plate in full culture medium. To label the cells,
MTT solution was added to the culture medium to a
final concentration of 1.2 mM and incubation was con-
tinued for another 4 hours. Dimethylsulphoxide was
then added and readings were taken on a plate reader at
570 nm with a reference wavelength of 690 nm. Read-
ings for day 0 and day 1 were taken 24 hours and
48 hours after plating the cells, respectively.
BrdU assay
Growing cells were incubated for 1 hour with Brdu (10
μM; Sigma) and the cells were trypsinised and fixed for
at least 30 minutes on ice with 70% ice cold ethanol.
The cells were then incubated with 2 M hydrochloric
acid for 30 minutes, washed and double-stained with an
anti-BrdU antibody (BD Biosciences) and propidium
iodide. Data were collected using an LSRII flow cyt-
ometer and results were analysed using FloJo software.
Apoptosis assay
Apoptosis was measured using FITC-conjugated Annexin
V. Cells were grown in normal culture medium, trypsi-
nised, washed twice in full medium and resuspended in
100 μl Annexin V binding buffer. Then 5 μlA n n e x i nV
(BD Biosciences) were added as well as propidium iodide
to a final concentration of 5 μg/ml, and the cells were
incubated at room temperature for 15 minutes in the
dark. Annexin V binding buffer (400 μl) was then added
and flow cytometry analysis was performed using an
LSRII flow cytometer. Nonapoptotic cells were negative
for both Annexin V and propidium iodide, early apopto-
tic cells were positive for Annexin V only, while cells
positive for both Annexin V and propidium iodide were
considered late apoptotic cells or already dead.
Immunofluorescence
For immunofluorescence staining, cells were grown on
glass coverslips or Lab-Tek permanox chamber slides
( V W R ,L u t t e r w o r t h ,U K ) .T h e yw e r et h e nf i x e di na
3.5% paraformaldehyde solution at room temperature
for 15 minutes, permeabilised with 0.1% Triton-X solu-
tion for 10 minutes, and washed and blocked in 0.1%
BSA solution for 15 minutes at room temperature. Cells
were stained with a rabbit polyclonal antibody against
N R 4 A 1f o r1h o u ra tr o o mt e m p e r a t u r ea n dw e r e
washed three times with PBS. Secondary antibody solu-
tion was added for 1 hour at room temperature and the
coverslips were then mounted. Images were visualised
using a Zeiss Axioplan 2 microscope, captured using an
AxioCam MRm camera, while image collection was con-
trolled by AxioVision software (Carl Zeiss Ltd).
Determination of EGF-mediated pathway activation
Confluent monolayers of control cells and MCF10A-
NR4A1 cells were grown in normal culture medium in
the absence of EGF and in the presence of 2% horse
serum overnight. Twelve wounds were scratched per
well of a six-well plate, and assay medium supplemented
with 20 ng/ml EGF was added. Protein lysates were col-
lected at different time points and were analysed for the
expression of phospho-ERK1/2 and total ERK1/2, AKT
and FAK by western blotting.
Statistical analysis
In each experiment the mean and standard deviation for
multiple wells was calculated using Excel. Statistical sig-
nificance (P < 0.05) was determined using the unpaired
two-tailed Student’s t test.
To determine the mean values obtained from repeats of
experiments, the mean value obtained for control cells in
each experiment was set as 100%. The percentage of
mean difference ± standard error (SE) between control
cells and cells ectopically expressing NR4A1, as well as
the statistical significance, were calculated by univariate
analysis of variance using the SPSS 15.0 software (SPSS,
Chicago, IL, USA). Yates’ chi-square test was used for the
clinical breast cancer/metastasis samples.
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RT-PCR analysis of differentially expressed transcription
factors identified in the differential tumour epithelial
transcriptome
The DTET comprises 8,051 transcripts that show a sig-
nificant difference in abundance between normal lumi-
nal epithelial cells and primary malignant epithelial cells,
and 640 of these transcripts belong to the family of
transcription factors [12].
Of the 640 differentially expressed transcription factors
that were identified as differential, 275 were chosen for
validation (Additional file 1). To confirm the differential
expression of these candidates, semiquantitative RT-PCR
analysis was performed using a pool of RNA from normal
luminal epithelial cells, RNA prepared from a minimally
immortalised normal epithelial cell line, a pool of RNA
from F19-negative (tumour cells negatively sorted with
the F19 antibody against fibroblast activation protein)
primary breast tumour preparations and a pool of RNA
extracted from solid tumours. Twenty-four transcription
factor genes were clearly identified as differentially
expressed (Table 1 and Additional file 2).
These 24 transcription factors were further analysed by
semiquantitative RT-PCR using a large panel of RNAs
extracted from normal cells, breast cancer cell lines, solid
breast tumours and F19-negative breast cancer cells.
While five of these genes were confirmed to be deregu-
lated in breast cancer (Figure 1a), our attention became
focused on the orphan nuclear receptor NR4A1 - which
was further confirmed to be upregulated twofold or more
compared with normal bre a s ti n9o u to ft h e1 6F 1 9 -
negative samples tested by real-time PCR (Figure 1b).
NR4A1 protein is expressed in breast tumours
To determine NR4A1 protein expression in breast
tumours, tissue microarrays of lobular and infiltrating
ductal carcinomas were used for immunohistochemistry.
In the normal attached breast tissue, NR4A1 cytoplasmic
staining was weak. Analysis of the pathological data showed
more prominent cytoplasmic staining levels in breast can-
cers and a negative association of NR4A1 with increasing
degrees of histological grade among the infiltrating duct
carcinomas, and hence invasive potential (Figure 1c and
Table 2). Only 14 out of 48 grade 3 infiltrating ductal carci-
nomas were positive for NR4A1, compared with 23 out of
31 grade 1/2 infiltrating ductal carcinomas (chi-squared test
P = 0.0002; Table 2). In some instances it was possible to
compare the primary tumours with their metastasis. Of the
series of grade 3 infiltrating carcinomas, 31 went on to
develop 41 brain metastasis. While the primary tumours
were positive in 16% (5/31) of cases, only 2% (1/41) of the
metastasis were positive for NR4A1 - further confirming its
negative association with higher degrees of invasive poten-
tial (Figure 1c and Table 2). The lobular carcinomas in the
present series all fell into the grade 2 category and also
showed a trend for increase of expression (chi-squared test
P = 0.12; Table 2) of NR4A1 compared with grade 3
primary infiltrating ductal carcinomas.
Ectopic expression of NR4A1 in MCF-10A cells
Since our data show that NR4A1 expression is increased
in primary tumours compared with normal breast (Fig-
ure 1) we examined its biological role in breast biology.
NR4A1 was ectopically expressed in the immortalised
mammary epithelial cell line MCF-10A using retroviral
vectors. Overexpression of NR4A1 was confirmed at the
mRNA level by RT-PCR (Figure 2a) and at the protein
level by western blotting (Figure 2b) and immunofluor-
escence (Figure 2c). NR4A1 was not detected in the par-
ental MCF-10A cells but it was readily detected upon
ectopic expression and localised to the nucleus.
NR4A1 decreases the migratory potential of MCF-10A
cells
To determine whether NR4A1 has an effect on MCF-
10A cell migration, control cells and MCF10A-NR4A1
Table 1 Genes deregulated in breast cancer according to
the first round of RT-PCR validation
Hugo
name
Reference sequence Regulation in
tumours
AEBP1 NM_001129 Upregulated
BCL6B NM_181844 Upregulated
BNC1 NM_001717 Downregulated
ELF5 NM_001422, NM_198381 Upregulated
ENPP2 NM_006209 Upregulated
HCLS1 NM_005335 Upregulated
HHEX NM_002729 Upregulated
HOXA3 NM_153631, NM_153632,
NM_030661
Downregulated
IRF4 NM_002460 Upregulated
KLF2 NM_016270 Upregulated
LASS4 NM_024552 Upregulated
LBP-9 NM_014553 Downregulated
LDB2 NM_001290 Upregulated
MEOX1 NM_004527/NM_013999 Upregulated
MTA1 NM_004689 Upregulated
NR4A1 NM_002135/NM_173157 Upregulated
PBX1 NM_002585 Upregulated
PHF13 NM_153812 Upregulated
ZMYND8 NM_012408, NM_183047,
NM_183048
Upregulated
SPDEF NM_012391 Upregulated
TCF8 NM_030751 Upregulated
TRIM29 NM_012101 Downregulated
ZNF114 NM_153608 Downregulated
ZNF277 NM_02994 Downregulated
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transcriptome. (a) Validation of 275 transcription factors that had been identified in the differential tumour epithelial transcriptome (DTET) to
be deregulated in breast tumours was performed by RT-PCR. The first round of validation, where pools of normal and tumour RNAs were used,
confirmed 24 genes to be deregulated in breast cancer. These 24 genes underwent a second round of RT-PCR validation in which RNAs from
individual solid and F19-negative breast cancer samples were used. Genes deregulated in breast cancers were considered those showing
differential expression in 50% or more of the F19-negative tumours compared with normal breast. The genes shown are the five transcription
factors identified by the DTET and confirmed by two rounds of RT-PCR validation to be deregulated in tumours. b2-microglobulin (b2 M) was
used as a loading control. (b) Real-time PCR was performed for NR4A1 expression using RNA from normal breast, breast organoids and F19-
negative tumours. Nine out of the 16 F19-negative tumours tested showed twofold or higher NR4A1 expression compared with normal breast
(F19.1, F19.4, F19.5, F19.7, F19.8, F19.10, F19.12, F19.14 and F19.15). (c) Immunohistochemical staining of breast tissue microarrays. (A) Normal
lobule (arrow) with weak staining in luminal cells and adjacent island of ductal carcinoma with positive staining. (B) Positive staining in grade 2
invasive and in situ lobular carcinoma. Negative staining in (C) primary high-grade ductal carcinoma and (D) its matched brain metastasis.
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tion assays.
Preliminary experiments of scratch wound assays
showed that EGF was required for MCF-10A cells to
close the wound, and that in its absence wounds
remained open even after 5 days (data not shown). The
assays were therefore performed in the presence of EGF,
and pictures of the same fields were taken at 0, 17 and
24 hours (Figure 3a). While control cells had almost
closed the wounds at 24 hours, the wounds of the
MCF10A-NR4A1 cells were still open at this time.
MCF10A-NR4A1 cells covered 49 ± 1.5% and 58 ± 1.8%
of the distance covered by the control cells at 17 hours
and 24 hours, respectively (mean ± SE, n =3 ,P < 0.001;
Table 2 Breakdown of the analysis of NR4A1 status in 160 breast carcinomas
Tumour status Histological type of carcinoma NR4A1 status Grade Proportion of positive cases Range of positivity
10 to 50% > 50%
Primary Lobular Present 2 36/81 (44%) 2/81 (2%) 34/81 (42%)
Primary IDC Present 1 and 2 23/31 (74%) 3/31 (9%) 20/31 (64%)
Primary IDC Present 3 14/48 (29%) 0 14/48 (29%)
Metastatic IDC Present 3 1/41 (2%) 0 1/41 (2%)
Table depicts grade, histological type, proportion and range of positivity. Samples with > 10% positive cells were considered positive. IDC, infiltrating duct
carcinoma.
Figure 2 NR4A1 overexpression in mammary epithelial cells. MCF-10A cells were infected either with a retroviral construct containing the
NR4A1 cDNA or with an empty vector control. Overexpression was confirmed at the mRNA level by (a) RT-PCR, and at the protein level by (b)
western blot and (c) immunofluorescence.
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fixed 17 hours after initiation of the scratch wound
assay shows that NR4A1 is expressed by the MCF10A-
NR4A1 cells at the edge of the wound (Additional file
3). Time-lapse microscopy was performed over a period
of 24 hours, confirming that wound closure occurred
due to cell spreading and migration and not due to cell
proliferation (Additional file 4 and 5). To confirm the
migration phenotype, control cells and MCF10A-NR4A1
cells were subjected to transwell assays and allowed to
Figure 3 NR4A1 reduces the migratory ability of MCF-10A cells. (a) A wound was scratched in a confluent monolayer of control and
MCF10A-NR4A1 cells. The edge of the wound was monitored over 24 hours and pictures of the same fields were taken at 0, 17 and 24 hours.
Scale bars: 300 μm. (b) Percentage migration. (c) To confirm the migration phenotype, cells were plated on the top chamber of transwells in the
absence of EGF and were allowed to migrate overnight towards medium supplemented with EGF present in the lower chamber. (d) To
compare the proliferation rate of control and MCF10A-NR4A1 cells, the MTT assay was performed. (e) The Annexin V assay was performed to
detect apoptosis in the two cell lines. Graphs show the mean ± standard deviation of representative experiments out of at least n =3 .* P <
0.001, **P < 0.005. PI, propidium iodide.
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in the bottom chamber. This assay showed a 32 ± 4.2%
reduction (mean ± SE, n =6 ,P <0 . 0 0 1 )i nt h em i g r a -
tion of the MCF10A-NR4A1 cells compared with con-
trol cells (Figure 3c), confirming the results obtained by
the scratch wound assay.
The MTT cell viability assay was also performed to
test whether a difference in cell proliferation could
account for the differences in cell migration observed
(Figure 3d). Importantly, no difference in the prolifera-
tion rate of the two cell lines was observed by this MTT
assay. Furthermore, flow cytometry analysis of cells
incubated with BrdU for 1 hour and stained with an
anti-BrdU antibody confirmed that the rate of BrdU
incorporation is similar between control cells and
MCF10A-NR4A1 cells (Table 3 and Additional file 6).
Similarly, no difference in the apoptotic index of control
cells and NR4A1-expressing cells was observed accord-
ing to the Annexin V apoptosis assay (Figure 3e and
Table 4).
NR4A1 reduces migration in normal mammary epithelial
cells and breast cancer cell lines
To determine whether the ability of NR4A1 to reduce
migration is specific to the MCF-10A cells, another nor-
mal mammary epithelial cell line (226L) ectopically
expressing NR4A1 (Figure 4a) was used in transwell
migration assays. Similarly to the MCF10A-NR4A1 cells,
226L-NR4A1 cells showed reduced migration since only
4 2±7 . 5 %( m e a n±S E ,n =3 ,P < 0.001) of these cells
migrated compared with controls (Figure 4b). To deter-
mine whether NR4A1 can reduce migration in tumour
cells, the breast tumour cell lines PMC42, ZR-75-1 and
MDA-MB-231 ectopically expressing NR4A1 (Figure 4a)
were used in transwell migration assays. NR4A1 reduced
tumour cell migration, since 61 ± 2.1% (mean ± SE, n =
3, P < 0.001) and 44 ± 5% (mean ± SE, n =3 ,P <
0.001) of PMC42-NR4A1 cells and ZR75-1-NR4A1 cells,
respectively, migrated compared with control cells. No
effect on the migration of the MDA-MB-231 cell line
was observed (Figure 4b).
Since the levels of NR4A1 inversely correlate with
tumour grade and invasiveness (Figure 1c), it was
important to determine whether NR4A1 also has the
ability to reduce tumour cell invasion. To determine
whether NR4A1 affects this process, the invasive lines
PMC42 and MDA-MB-231 were used in transwell inva-
sion assays. NR4A1 had no effect on the invasion of
either cell line through matrigel (Figure 4c).
NR4A1 has no effect on the proliferation rate or
apoptosis index of any of the lines tested, as determined
by BrdU incorporation and the Annexin V apoptosis
assay, respectively (Tables 3 and 4, and Additional file 6
and 7).
NR4A1 alters the ability of MCF-10A cells to adhere to the
extracellular matrix and integrin cell surface expression
Since cell adhesion and migration are two processes
linked to each other, the ability of NR4A1 cells to
adhere to the ECM was tested. MCF10A-NR4A1 cells
showed increased adhesion to fibronectin (23 ± 4%,
mean ± SE, n =5 ,P < 0.001) and decreased adhesion to
collagen type I (30 ± 3%, mean ± SE, n =3 ,P < 0.001),
while both control cells and MCF10A-NR4A1 cells
adhered to vitronectin and laminin I at similar levels
(Figure 5a).
Since the primary receptors for cell interaction with
the ECM are integrins, flow cytometry analysis was per-
formed to test whether the differences in the adhesion
profile of the cells would be reflected in their cell sur-
face integrin expression. Flow cytometry analysis for the
expression of cell surface integrins showed that
MCF10A-NR4A1 cells had an average of 61 ± 4.8%
(mean ± SE, n =6 ,P < 0.001) higher expression of a5
integrin and 73 ± 7.8% higher expression of b4 integrin
(mean ± SE, n =5 ,P < 0.001) compared with control
cells (Figure 5b). Since a5 integrin is the alpha subunit
of the a5b1 fibronectin receptor, increased levels of this
integrin in the MCF10A-NR4A1 cells may be responsi-
ble for their increased adhesion to fibronectin (Figure
5a). Furthermore, no differences in the levels of avb6
integrin, another receptor for fibronectin, were observed.
Although reduced adhesion to collagen type I was
observed (Figure 5a), the expression of integrins a1 and
a2 that form the collagen receptors a1b1 and a2b1 was
the same between the two cell lines. Despite the fact
that b4 integrin forms one of the main laminin receptors
a6b4, the increased levels of the b4 subunit did not
result in increased adhesion to laminin I. Finally, no dif-
ferences in the levels of b1, avb3 and a6 integrins were
observed (Figure 5b).
NR4A1 expression affects the ERK1/2 pathway
Initial experiments (data not shown) showed that EGF is
necessary for MCF-10A cell migration in the scratch
Table 3 Summary of data from flow cytometry analysis
of BrdU incorporation in normal and tumour lines
Cells % BrdU incorporation Significant*
Control cells NR4A1 cells
MCF-10A (n = 3) 22 ± 1.7 20 ± 0.1 No
PMC42 (n = 3) 50 ± 1 42 ± 3.6 No
ZR-75-1 (n = 2) 24 21 N/A
MDA-MB-231 (n = 3) 33 ± 5 33 ± 3.5 No
226L (n = 3) 18 ± 2.7 16 ± 4.6 No
Data presented as mean ± standard error. *P < 0.05 by paired Student’s t test.
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Cells Annexin V positive cells
(%)
Annexin V and propidium iodide positive cells
(%)
Total Annexin V positive cells
(%)
MCF10A-cotntrol (n = 2) 1.7 1.6 3.3
MCF10A-NR4A1 (n =2 ) 1 1 2
PMC42-control (n = 3) 3 ± 1.1 8 ± 1.2 11 ± 2
PMC42-NR4A1 (n = 3) 1.5 ± 0.5 7 ± 0.8 8.5 ± 0.7
ZR75-1-control (n = 3) 1.8 ± 0.5 11 ± 1.2 12.8 ± 1.7
ZR75-1-NR4A1 (n = 3) 1.6 ± 0.6 13 ± 2.8 14.6 ± 2.3
MDA-MB-231-control
(n =3 )
2.3 ± 0.6 10 ± 2 12.3 ± 2.5
MDA-MB-231-NR4A1
(n =3 )
2 ± 0.6 8 ± 1 10 ± 1.3
226L-control (n = 3) 6 ± 0.6 14 ± 1 20 ± 0.3
226L-NR4A1 (n = n = 3) 3.6 ± 1 10 ± 1.7 13.6 ± 1.5
Data presented as mean ± standard error.
Figure 4 NR4A1 reduces the migratory ability of breast cancer lines. NR4A1 was ectopically expressed in three breast cancer lines (ZR-75-1,
PMC42 and MDA-MB-231) and one normal mammary epithelial cell line (226L). (a) Ectopic expression was confirmed at the protein level by
western blot. (b) The cell lines were then used for transwell migration assays where cells were allowed to migrate for 8 hours (226L and MDA-
MB-231) or overnight (PMC42 and ZR-75-1) towards full culture medium. In all lines apart from MDA-MB-231, NR4A1 reduced the migratory
ability of the cells. (c) The invasive lines PMC42 and MDA-MB-231 were used in transwell invasion assays. Cells were allowed to invade through
the matrigel-coated transwells for 8 hours (MDA-MB-231) or overnight (PMC42). NR4A1 expression had no effect on the invasion of the tumour
lines. Graphs show the mean ± standard deviation of one representative experiment out of n =3 .* P < 0.001. C, control; N, NR4A1.
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EGF binding to the EGF receptor are the mitogen-acti-
vated protein kinase (MAPK) pathway and the phos-
phoinositide 3-kinase (PI3K) pathway [17]; both
pathways have been shown to be involved in EGF-
mediated epithelial cell migration [18-20].
To test whether NR4A1 affects the ERK/MAPK path-
way, EGF-starved cells were treated with EGF and pro-
tein lysates were collected at different time points and
tested for the expression of activated ERK1/2 (Figure 6a,
c). Although the initial activation of ERK1/2 was the
same in both control and MCF10A-NR4A1 cells (5 min-
utes), the NR4A1-expressing cells had lower levels of
active ERK1/2 at later time points (4 to 10 hours). The
importance of the ERK/MAPK pathway in MCF-10A
cell migration was confirmed by repeating the scratch
wound assay in the presence of a MEK1/2 inhibitor
(U0126). The inhibitor reduced the migration of both
control cells and MCF10A-NR4A1 cells (Figure 6d). On
the other hand, the PI3K pathway did not seem to be
affected as the levels of phospho-AKT were similar in
both cell lines (Figure 6b). Finally, no differences in the
levels of phospho-FAK were observed (Figure 6b).
Discussion
Breast cancer is the most common cancer in European
women, accounting for more than one-quarter of all
female cancers. Despite the great progress observed in
Figure 5 Effect of NR4A1 on cell adhesion and integrin expression. (a) Control or MCF10A-NR4A1 cells were plated on wells coated with
fibronectin, collagen type I, vitronectin or laminin I. Attached cells were fixed and stained with crystal violet. MCF10A-NR4A1 cells show
increased adhesion to fibronectin and decreased adhesion to collagen type I compared with control cells, while both cell lines show similar
adhesion levels to vitronectin and laminin I (mean ± standard deviation of six wells, *P < 0.001). (b) MCF10A-NR4A1 cells or control cells were
analysed by flow cytometry for the cell surface expression of the integrins depicted. MCF10A-NR4A1 cells have increased levels of a5 and b4
integrins.
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breast tumours, the need for further therapeutic targets
has been recently emphasised [21]. Hence, there remains
a need for the identification of new genes that can be
used in diagnosis, prognosis and therapy.
In our study, NR4A1 was first identified in the DTET
as one of the transcription factors upregulated in pri-
mary breast tumours [12]. Validation of these results by
semiquantitative and real-time PCR confirmed the
increased expression of NR4A1 in tumour cells (Figure
1a, b). Immunohistochemical analysis showed that
NR4A1 protein is indeed expressed in tumours but only
weakly in normal cells, and interestingly that its expres-
sion is downregulated in higher grade and metastatic
tumours (Figure 1c and Table 2). These data prompted
us to study the role of NR4A1 in mammary epithelial
cell biology.
NR4A1 belongs to the NR4A family of nuclear recep-
tors that also includes Nurr1 (NR4A2) and NOR-1
(NR4A3). No physiological ligand has been reported for
the NR4A nuclear receptors, which are therefore classi-
fied as orphan receptors. NR4A family members are
stress/immediate early response genes that can be
induced by several signals such as stress, inflammatory
cytokines, phorbol esters, peptide hormones, growth fac-
tors and neurotransmitters [22-27]. They play a role in
the central nervous system, steroidogenesis, inflamma-
tion, cell survival and cell death [28-32].
NR4A1 is considered a mediator/regulator of cell sur-
vival and apoptosis in tumours. Several apoptotic agents
- including etoposide, phorbol esters, calcium iono-
phore, retinoids and butyrate - induce the levels of
NR4A1 and lead to its translocation from the nucleus to
mitochondria, where it interacts with Bcl-2 and converts
the latter into an inducer of apoptosis. NR4A1 has been
shown to mediate apoptosis in several tumour cell lines,
including prostate cancer cells, colon cancer cells, breast
cancer cells and melanoma cells [29,33-36]. On the
Figure 6 NR4A1 affects the levels of active ERK1/2 during migration. Confluent monolayers of control cells and MCF10A-NR4A1 cells were
grown in normal culture medium in the absence of epidermal growth factor (EGF) and in the presence of 2% horse serum overnight. Twelve
wounds were scratched per well and 20 ng/ml EGF was added for the time indicated. Protein lysates were analysed for the expression of (a)
phospho-ERK1/2 and (b) phosphor-AKT and phospho-FAK. (c) Summary of results for active ERK1/2 from three or more experiments (mean ±
standard deviation, *P < 0.05). (d) Confluent monolayers of control and MCF10A-NR4A1 cells were treated for 1 hour with 10 μM U0126
inhibitor. Wounds were then scratched and the cells were allowed to migrate for 17 hours in the presence of the inhibitor in EGF-supplemented
medium. Pictures of the same fields were taken at 0 and 17 hours. A representative experiment is shown out of three performed.
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cycle progression in lung cancer cells, showing a
requirement for its DNA-binding domain and transacti-
vation [25], while it also mediates the mitogenic effects
of vascular endothelial growth factor A, and NR4A1 null
mice injected with melanoma cells show reduced
tumour formation and angiogenesis [37].
The above studies suggest that NR4A1 plays distinct
roles depending on the cell context and signal stimula-
tion, and suggest that modulation of NR4A1 activity
may be used as an anticancer therapy. Interestingly,
knockout mice that are null for both NR4A1 and NOR1
develop acute myeloid leukaemia due to abnormal mye-
loid cell proliferation and apoptosis. Both transcripts
have been shown in humans to be downregulated in
patients with acute myeloid leukaemia [38]. While
NR4A1 is expressed in melanoma tissues, its expression
appears to decline in metastatic melanomas [36]. Finally,
analysis of metastatic adenocarcinomas of diverse origin
and comparison with primary adenocarcinomas of the
same tumour spectrum identified NR4A1 as part of a
17-gene signature associated with metastasis as one of
the downregulated genes [8]. The data from the present
study are in agreement with the above studies, since
they show NR4A1 cytoplasmic expression in primary
tumours that is reduced in higher grade and metastatic
tumours (Figure 1c and Table 2). Since cytoplasmic
NR4A1 has been shown to mediate apoptosis in several
cancer cell lines, its reduced expression in higher grade
and metastatic tumours may possibly contribute to the
survival of such tumour cells.
The above results prompted us to study the role of
NR4A1 expression in mammary epithelial cells. For this
purpose, the normal mammary epithelial cell line MCF-
10A was infected with a retroviral construct containing
the NR4A1 cDNA, and ectopic expression was con-
firmed both at the mRNA and protein levels (Figure 2).
Interestingly, ectopically expressed NR4A1 was present
in the nucleus and not in the cytoplasm of MCF10A-
NR4A1 cells grown under normal culture conditions
(Figure 2c). During characterisation of the MCF10A-
NR4A1 cells, data obtained from both scratch wound
a n dt r a n s w e l lm i g r a t i o na s s a y ss h o w e dt h a tN R 4 A 1
reduces the migratory ability of MCF-10A cells (Figure
3a to 3c). As NR4A1 can act both as a prosurvival and a
proapoptotic agent depending on the cell context and
stimulus, it was important to confirm that the results
obtained regarding the cell migration phenotype were
not due to differences in the proliferation or apoptosis
of the two cell lines. Indeed the data from the MTT cell
proliferation assay that measures mitochondrial activity
showed no differences in cell viability and proliferation
between control and MCF10A-NR4A1 cells (Figure 3d).
Similar results were obtained by the BrdU incorporation
assay (Table 3 and Additional file 6). Furthermore, no
differences in apoptosis were observed according to the
Annexin V staining (Figure 3e and Table 4). Time-lapse
microscopy also confirmed that both cell lines migrated
through spreading and not through proliferation (Addi-
tional file 4 and 5).
To test whether the ability of NR4A1 to reduce migra-
tion is specific to MCF-10A cells, another normal mam-
mary epithelial cell line ectopically expressing NR4A1
(226L cell line, prepared in our laboratory) was used for
transwell migration assays. The results obtained showed
that NR4A1 also reduces migration in the 226L cells
and therefore that its effect in not specific to the MCF-
10A cells. As NR4A1 levels decline in higher grade
tumours, it was hypothesised that NR4A1 may have an
adverse effect on the migratory ability of tumour cells.
Three breast cancer lines ectopically expressing NR4A1
(PMC42, ZR-75-1 and MDA-MB-231) were used to per-
form transwell migration assays. NR4A1 was able to
reduce the migration in two out of the three lines tested
(PMC42 and ZR-75-1; Figure 4b). As several studies
have previously suggested that NR4A1 induces tumour
cell apoptosis [29,33-36], the Annexin V assay was per-
formed - showing that, in the case of the tumour lines
tested, NR4A1 did not affect cell apoptosis (Table 4 and
Additional file 7). The downregulation of NR4A1 in
breast cancers of higher grade is therefore possibly due
to its adverse effect on the migration of the tumour
cells. As NR4A1 is downregulated in higher grade, more
invasive tumours, it was also possible that it may have
an effect on the invasive ability of tumour cells. How-
ever, no difference in the invasion of PMC42 and MDA-
MB-231 cells through matrigel was observed (Figure 4c).
Cell adhesion to the ECM is important for the organi-
sation and function of epithelial tissues. The main recep-
tors for cell-ECM interaction are integrins, while heparan
sulphate proteoglycans are also involved in this process
[39]. Cell adhesion and migration are two processes
linked to each other. Since NR4A1 was found to alter the
migratory ability of MCF-10A cells, it was hypothesised
that it would also alter their ability to adhere to ECM.
Our results showed that NR4A1 enhances the adhesion
of MCF-10A cells to fibronectin and reduces their adhe-
sion to collagen type I, while it does not affect adhesion
to vitronectin or laminin I (Figure 5a). Integrin expres-
sion profiling showed that MCF-10A cells have higher
levels of a5 integrin, which along with the b1 subunit
forms the a5b1 integrin receptor, one of the fibronectin
receptors, as well as higher levels of b4 integrin (Figure
5b). As no difference in the levels of the avb6 fibronectin
receptor was observed, this supports the hypothesis that
increased adhesion to fibronectin is possibly through the
a5b1 receptor. Interestingly, no differences in the expres-
sion levels of the a1 and a2 integrins that form the
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the reduction in the adhesion of MCF10A-NR4A1 cells
to collagen type I. It is therefore possible that the reduc-
tion in collagen adhesion in the latter cells is due to
reduced levels of active integrins on the cell surface and
not due to differences in expression levels. No differences
in the ability of the cells to adhere to laminin I were
observed, despite the increase in the levels of b4 integrin
that forms one of the major receptors (a6b4) for adhesion
to this ECM. This therefore suggests that, in the case of
the MCF-10A cells, adhesion to laminin I occurs through
a different integrin pair.
In cell migration, although the formation of integrin-
mediated adhesions is required to create traction for
cells to move, too strong adhesions or their reduced
turnover inhibit migration. The reduced migration of
MCF10A-NR4A1 cells may therefore be due to
increased integrin levels. Our preliminary data using
blocking antibodies against a5 or b4 integrins, however,
do not support this hypothesis. The importance of b4
integrin in promoting breast cancer cell invasion and
survival has previously been demonstrated [40]. Since
NR4A1 appears to have an adverse effect on tumour
cells, further studies will be conducted to determine
whether NR4A1 actually regulates b4 integrin expression
in breast tumour cells.
EGF induces robust migration in MCF-10A cells (our
results; see also [18]) and the ERK/MAPK pathway has
been shown to be involved in the process [18]. Our data
showed that the initial EGF-mediated activation of the
ERK/MAPK pathway is similar in both cell lines. The
levels of active ERK1/2, however, appear to decline fas-
ter in the MCF10A-NR4A1 cells compared with the
control ones (Figure 6a, c). Inhibition of the ERK/
MAPK pathway resulted in reducing the migration of
both control cells and MCF10A-NR4A1 cells (Figure
6d). The reduced levels of active ERK1/2 may therefore
contribute towards the migratory phenotype of the
MCF10A-NR4A1 cells.
Our data propose that nuclear NR4A1 may play a pro-
tective role against breast cancer metastasis as it acts to
inhibit both normal and tumour cell migration. Our
immunohistochemical data (Figure 1c and Table 2) also
suggest that NR4A1 may play a protective role against
metastasis, although the expression in this case was
cytoplasmic. Higher grade 3 breast cancers (that is,
those with a potentially poorer prognosis and the
greater likelihood of metastasis in due course) are less
likely to contain demonstrable levels of NR4A1. Breast
cancer of all grades possesses the potential to spread
and metastasise. This spread is less common with grade
2 lesions than those of grade 3, but it does occur. There
is thus a continuum of invasive potential not indicated
solely by the histological features. These tumours within
each grade that possess demonstrable NR4A1 may
therefore be those that are less likely to spread. Further
studies with detailed follow-up and in comparison with
other known prognostic factors will be needed to prove
or disprove such a hypothesis.
Conclusions
In summary, our study has shown that NR4A1 expres-
sion is reduced in metastatic breast tumours. NR4A1
has the ability to reduce the migration of breast tumour
cells as well as the ability to reduce migration, to alter
the adhesion to ECM and integrin cell surface expres-
sion of normal mammary epithelial cells. Further studies
are being conducted to delineate the pathways involved
in the phenotype observed.
Acknowledgements
The present work was conducted as part of the Hilton-
Ludwig Cancer Metastasis Initiative, funded by the Con-
rad N. Hilton Foundation and the Ludwig Institute for
Cancer Research Ltd. PSJ gratefully acknowledges finan-
cial support from the Wellcome Trust (078305). The
authors are also grateful to Dr Ayad Eddaoudi and
Prabhjoat Chana at the flow cytometry core facility,
Camelia Botnar Laboratories, Great Ormond Street Hos-
pital for their help and advice on flow cytometry. They
would also like to thank Mr Andrew Vaughan at the
MRC Laboratory for Molecular Cell Biology & Cell Biol-
ogy Unit, University College London, for his help in set-
ting up the live imaging experiment.
Additional material
Additional file 1: RT-PCR validation. A table showing the gene name,
accession number and primer set used for the two rounds of RT-PCR
validation.
Additional file 2: Transcription factors identified to be differentially
expressed between normal breast and primary tumours. Twenty-four
transcription factors were identified in the first round of RT-PCR
validation to be differentially expressed between normal breast and
primary tumours. Two hundred and seventy-five transcription factors
identified to be differentially expressed in the DTET underwent the first
round of RT-PCR validation using a pool of RNA from normal luminal
epithelial cells, a pool of RNA from primary tumours, a pool from F19-
negative tumours and RNA from the normal mammary epithelial cell line
226L. Twenty-four transcription factors were confirmed to be deregulated
in tumours in the first round of RT-PCR validation. GAPDH or b2-
microglobulin (b2 M) was used as loading controls.
Additional file 3: NR4A1 is expressed by cells at the edge of the
wound in MCF-10A cells ectopically expressing NR4A1. A wound
was scratched in a confluent monolayer of MCF10A-NR4A1 or control
cells. The cells were allowed to migrate into the wound overnight. They
were then fixed and stained with (A) an anti-NR4A1 antibody and (B)
Dapi. Scale bars: 50 μm.
Additional file 4: Time-lapse microscopy. Control and MCF10A-NR4A1
cells were plated on 35 mm dishes and were allowed to reach
confluency. Wounds were scratched using a 200 μl yellow tip and cell
migration was monitored over a period of 24 hours, while images of the
same fields were taken every 10 minutes. Time-lapse microscopy
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Page 15 of 17confirms the reduced rate of migration of MCF10A-NR4A1 cells
(Additional file 5) compared with control cells, and shows that wound
closure indeed occurs by cell spreading rather than cell proliferation.
Additional file 5: Time-lapse microscopy showing migration of
MCF10A-NR4A1 cells. Control cells and MCF10A-NR4A1 cells were
plated on 35 mm dishes and were allowed to reach confluency. Wounds
were scratched using a 200 μl yellow tip and cell migration was
monitored over a period of 24 hours, while images of the same fields
were taken every 10 minutes. Time-lapse microscopy confirms the
reduced rate of migration of MCF10A-NR4A1 cells compared with control
cells (Additional file 4), and shows that wound closure indeed occurs by
cell spreading rather than cell proliferation.
Additional file 6: Flow cytometry analysis of BrdU incorporation in
normal and tumour breast cell lines. Normal and breast cancer cell
lines were incubated with BrdU for 1 hour at 37°C. The cells were then
stained with an anti-BrdU antibody and analysed by flow cytometry. No
significant differences in the rate of entry into S phase were observed
between control cells and cells ectopically expressing NR4A1.
Additional file 7: NR4A1 does not induce apoptosis in the normal
and breast cancer lines tested. Growing cells were collected and the
Annexin V assay was performed to detect apoptosis. No differences in
the apoptotic index between control cells and cells ectopically
expressing NR4A1 were observed.
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